Open AccessClinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
Author(s) -
Wang Hanping,
Guo Xiaoxiao,
Zhou Jiaxin,
Li Yue,
Duan Lian,
Si Xiaoyan,
Zhang Li,
Liu Xiaowei,
Wang Mengzhao,
Shi Juhong,
Zhang Li
Publication year - 2020
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13240
Subject(s) - medicine , pneumonitis , immune system , immune checkpoint , adverse effect , lung , immunotherapy , disease , hypersensitivity pneumonitis , cancer research , immunology
The increasing use of immune checkpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immune checkpoint inhibitors, mainly activated T‐cells, can attack normal tissues and organs in the body and lead to a variety of adverse effects. In the lung, these attacks can induce checkpoint inhibitor pneumonitis (CIP). CIP is different from known pulmonary interstitial pneumonitis, and has the potential to be fatal if not treated correctly. In this review, we summarize the characteristics of CIP and provide advice on how to manage this disease.